ARS Pharmaceuticals Faces Securities Fraud Lawsuit

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has been named in a class action lawsuit alleging securities fraud. The lawsuit covers purchasers of the company's securities during the period from March 9, 2026, through June 24, 2026.

According to the complaint, ARS Pharmaceuticals may have made misleading statements to investors about its business and future prospects. Rosen Law Firm, an investor rights law firm, announced it is bringing the action on behalf of investors.

The filing of the class action suit follows allegations of misrepresentations or omissions that may have impacted the value of ARS Pharmaceuticals stock during the specified period. Specific details of the alleged misstatements have not yet been publicly detailed.

The company has not issued a statement regarding the lawsuit. Investors are advised to review the lawsuit's details and consider consulting legal counsel.